PharmacoEconomics and Outcomes News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.STEP-KOA knee osteoarthritis programme is cost effective in VA population in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
MRI-guided IV alteplase therapy worth it for stroke with unknown time of onset in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Empagliflozin less costly than other branded AHAs for T2DM patients with CVD in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
NICE draft guidance recommends dapagliflozin for some patients with chronic kidney disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Suboptimal lipid-lowering therapy in secondary prevention of atherosclerotic CVD incurs high cost in Italy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Acute care costs of neonatal sepsis and meningitis in Africa
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
No benefit of peritoneal dialysis over haemodialysis for uninsured ESKD patients in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
NZ's Pharmac negotiates deal for Roche's monoclonal antibodies for COVID-19
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Tumour molecular classification-guided treatment cost effective for stage I or II high-risk EC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Oral semaglutide a cost-effective option for patients with uncontrolled T2DM
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Unilateral cochlear implants cost effective in adults in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Cancer care in the USA presents substantial economic burden for patients
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
PCSK9 inhibitors not cost effective versus other antihyperlipidaemics
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
